AU2001279064A1 - Therapeutic azo-compounds for drug delivery - Google Patents
Therapeutic azo-compounds for drug deliveryInfo
- Publication number
- AU2001279064A1 AU2001279064A1 AU2001279064A AU7906401A AU2001279064A1 AU 2001279064 A1 AU2001279064 A1 AU 2001279064A1 AU 2001279064 A AU2001279064 A AU 2001279064A AU 7906401 A AU7906401 A AU 7906401A AU 2001279064 A1 AU2001279064 A1 AU 2001279064A1
- Authority
- AU
- Australia
- Prior art keywords
- azo
- therapeutic
- compounds
- drug delivery
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22099800P | 2000-07-27 | 2000-07-27 | |
US60/220,998 | 2000-07-27 | ||
PCT/US2001/023748 WO2002009769A2 (en) | 2000-07-27 | 2001-07-27 | Therapeutic azo-compounds for drug delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001279064A1 true AU2001279064A1 (en) | 2002-02-13 |
Family
ID=22825907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001279064A Abandoned AU2001279064A1 (en) | 2000-07-27 | 2001-07-27 | Therapeutic azo-compounds for drug delivery |
Country Status (3)
Country | Link |
---|---|
US (3) | US6602915B2 (en) |
AU (1) | AU2001279064A1 (en) |
WO (1) | WO2002009769A2 (en) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7985415B2 (en) * | 1997-09-10 | 2011-07-26 | Rutgers, The State University Of New Jersey | Medical devices employing novel polymers |
US6486214B1 (en) * | 1997-09-10 | 2002-11-26 | Rutgers, The State University Of New Jersey | Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
US7122615B1 (en) | 1998-09-10 | 2006-10-17 | Rutgers, The State University Of New Jersey | Polyanhydrides with therapeutically useful degradation products |
US6468519B1 (en) * | 1997-09-10 | 2002-10-22 | Rutgers, The State University Of New Jersey | Polyanhydrides with biologically active degradation products |
US20040038948A1 (en) | 1999-12-07 | 2004-02-26 | Uhrich Kathryn E. | Therapeutic compositions and methods |
AU2001279064A1 (en) * | 2000-07-27 | 2002-02-13 | Rutgers, The State University | Therapeutic azo-compounds for drug delivery |
MXPA03000821A (en) | 2000-07-27 | 2004-03-18 | Univ Rutgers | Therapeutic polyesters and polyamides. |
ES2323771T3 (en) | 2001-11-23 | 2009-07-24 | Rutgers, The State University | IMPROVED SYNTHESIS OF POLIANHYDRATES. |
WO2004006863A2 (en) * | 2002-07-17 | 2004-01-22 | Rutgers, The State University | Therapeutic devices for patterned cell growth |
US7825106B2 (en) | 2003-09-03 | 2010-11-02 | Agi Therapeutics Ltd. | Modified release formulations and methods of treating inflammatory bowel disease |
US7737133B2 (en) | 2003-09-03 | 2010-06-15 | Agi Therapeutics Ltd. | Formulations and methods of treating inflammatory bowel disease |
WO2005110485A1 (en) * | 2004-05-14 | 2005-11-24 | Interface Biologics Inc. | Polymeric coupling agents and pharmaceutically-active polymers made therefrom |
CA2467321A1 (en) * | 2004-05-14 | 2005-11-14 | Paul J. Santerre | Polymeric coupling agents and pharmaceutically-active polymers made therefrom |
JP2008545695A (en) * | 2005-05-23 | 2008-12-18 | ラトガーズ, ザ ステイト ユニバーシティ オブ ニュー ジャージー | Rapid degradation polymer |
US7741359B2 (en) * | 2005-05-27 | 2010-06-22 | Antibe Therapeutics Inc. | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs |
WO2006125293A1 (en) * | 2005-05-27 | 2006-11-30 | Antibe Therapeutics Inc. | Derivatives of 4- or 5-aminosalicylic acid |
US7498355B2 (en) * | 2005-05-27 | 2009-03-03 | Antibe Therapeutics Inc. | Derivatives of 4- or 5-aminosalicylic acid |
RU2008152751A (en) * | 2006-06-06 | 2010-07-20 | Антиб Терапьютикс Инк. (Ca) | Salts of trimebutine and n-desmethyltrimebutine |
EP2032614A2 (en) * | 2006-06-06 | 2009-03-11 | Rutgers, The State University Of New Jersey | Iodinated polymers |
WO2008034019A2 (en) | 2006-09-13 | 2008-03-20 | Polymerix Corporation | Active agents and their oligomers and polymers |
US8747832B2 (en) * | 2007-04-12 | 2014-06-10 | Rutgers, The State University Of New Jersey | Biodegradable polyanhydrides with natural bioactive molecules |
US8741317B2 (en) | 2010-08-19 | 2014-06-03 | Rutgers, The State University Of New Jersey | Slow-degrading polymers comprising salicylic acid for undelayed and sustained drug delivery |
WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
AU2013257706A1 (en) | 2012-05-07 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for the treatment of neurological disorders |
AU2013257742A1 (en) | 2012-05-07 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
WO2013168016A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
WO2013175357A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory bowel disease |
CN104603097A (en) | 2012-05-23 | 2015-05-06 | 塞利克斯比奥私人有限公司 | Compositions and methods for the treatment of multiple sclerosis |
US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
US9765020B2 (en) | 2012-05-23 | 2017-09-19 | Cellix Bio Private Limited | Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis |
WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
US9144579B2 (en) | 2012-08-17 | 2015-09-29 | Rutgers, The State University Of New Jersey | Polyesters and methods of use thereof |
WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
AU2013311349A1 (en) | 2012-09-08 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for treatment of inflammation and lipid disorders |
US20140120057A1 (en) | 2012-10-25 | 2014-05-01 | Rutgers, The State University Of New Jersey | Polymers and methods thereof for wound healing |
US9387250B2 (en) | 2013-03-15 | 2016-07-12 | Rutgers, The State University Of New Jersey | Therapeutic compositions for bone repair |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9862672B2 (en) | 2013-05-29 | 2018-01-09 | Rutgers, The State University Of New Jersey | Antioxidant-based poly(anhydride-esters) |
EP3004049B1 (en) | 2013-06-04 | 2018-09-05 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
US10023521B2 (en) | 2014-06-13 | 2018-07-17 | Rutgers, The State University Of New Jersey | Process and intermediates for preparing poly(anhydride-esters) |
SG11201706952VA (en) | 2014-09-26 | 2017-10-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of epilepsy and neurological disorders |
CA2967908C (en) | 2014-09-29 | 2020-11-17 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
WO2016098119A1 (en) | 2014-10-27 | 2016-06-23 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
EP3242869B1 (en) | 2015-01-06 | 2021-10-27 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammation and pain |
US10543162B2 (en) | 2015-04-10 | 2020-01-28 | Rutgers, The State University Of New Jersey | Kojic acid polymers |
JP2021512852A (en) | 2018-02-02 | 2021-05-20 | リップル セラピューティクス コーポレーション | Glass preparation containing steroid dimer and its use |
MX2022013665A (en) | 2020-05-01 | 2022-11-30 | Ripple Therapeutics Corp | Heterodimer compositions and methods for the treatment of ocular disorders. |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE288311C (en) | 1915-10-27 | |||
DE288387C (en) | ||||
US4062855A (en) | 1971-09-27 | 1977-12-13 | University Of Washington | Synthetic polymers furnishing controlled release of a biologically active component during degradation |
US4190445A (en) * | 1975-03-20 | 1980-02-26 | Canon Kabushiki Kaisha | Electrophotographic photosensitive media and process for manufacturing thereof |
US4298595A (en) * | 1978-12-20 | 1981-11-03 | Dynapol | Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract |
US4190716A (en) * | 1978-12-20 | 1980-02-26 | Dynapol | Polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract |
US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
US4757128A (en) | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
US4888176A (en) | 1984-05-21 | 1989-12-19 | Massachusetts Institute Of Technology | Controlled drug delivery high molecular weight polyanhydrides |
US4886870A (en) | 1984-05-21 | 1989-12-12 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
US4891225A (en) | 1984-05-21 | 1990-01-02 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
CH671402A5 (en) | 1985-10-02 | 1989-08-31 | Sandoz Ag | |
DE3670206D1 (en) | 1986-05-20 | 1990-05-17 | Massachusetts Inst Technology | BIOERODABLE PRODUCTS FOR USE AS IMPLANTS OR PROSTHESIS WITH A PREDICTABLE LEVEL OF RESORBATION. |
US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
US4857311A (en) | 1987-07-31 | 1989-08-15 | Massachusetts Institute Of Technology | Polyanhydrides with improved hydrolytic degradation properties |
US5259968A (en) | 1988-02-29 | 1993-11-09 | Exxon Chemical Patents Inc. | Dispersant additive comprising the reaction product of a polyanhydride and a mannich condensation product |
US4868274A (en) | 1988-05-23 | 1989-09-19 | Hoechst Celanese Corp. | Polyanhydride from carboxy aryloxy alkanoic acid |
US5356630A (en) | 1989-02-22 | 1994-10-18 | Massachusetts Institute Of Technology | Delivery system for controlled release of bioactive factors |
US4999417A (en) | 1989-03-30 | 1991-03-12 | Nova Pharmaceutical Corporation | Biodegradable polymer compositions |
US5487897A (en) | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
US4997904A (en) | 1989-08-25 | 1991-03-05 | Nova Pharmaceutical Corporation | Aromatic polyanhydride compositions |
CA2072360A1 (en) | 1989-12-26 | 1991-06-27 | Abraham J. Domb | Prodrug anhydride compositions |
US5175235A (en) | 1990-06-04 | 1992-12-29 | Nova Pharmaceutical Corporation | Branched polyanhydrides |
NL9000237A (en) | 1990-01-31 | 1991-08-16 | Re Novative Drugs For Dermatol | Topical medicaments contg. 5-amino-salicylic acid - for treating inflammatory, erosive or ulcerative disorders of oral cavity or vagina |
US5082925A (en) | 1990-08-16 | 1992-01-21 | Ethicon, Inc. | Homopolymers and copolymers of salicylate lactones |
EP0558556B1 (en) | 1990-11-19 | 1997-04-23 | Cornell Research Foundation, Inc. | Hyperbranched polyesters |
US5518730A (en) | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
US5264540A (en) | 1992-07-20 | 1993-11-23 | Ethicon, Inc. | Aromatic polyanhydrides |
US5889028A (en) * | 1996-02-09 | 1999-03-30 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
IE960308A1 (en) | 1996-04-23 | 1997-11-05 | Kinerton Ltd | Sustained release ionic conjugate |
DE69821600T2 (en) | 1997-02-18 | 2005-01-05 | Rutgers, The State University | MONOMERS DERIVED FROM HYDROXYLIC ACIDS AND POLYMERS MANUFACTURED THEREOF |
US6468519B1 (en) | 1997-09-10 | 2002-10-22 | Rutgers, The State University Of New Jersey | Polyanhydrides with biologically active degradation products |
WO1999012990A1 (en) | 1997-09-10 | 1999-03-18 | Rutgers, The State University | Polyanhydrides with therapeutically useful degradation products |
US6486214B1 (en) | 1997-09-10 | 2002-11-26 | Rutgers, The State University Of New Jersey | Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
DE19754063A1 (en) | 1997-12-05 | 1999-06-10 | Bayer Ag | Degradation of biodegradable polymers |
US6153212A (en) | 1998-10-02 | 2000-11-28 | Guilford Pharmaceuticals Inc. | Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same |
MXPA03000821A (en) | 2000-07-27 | 2004-03-18 | Univ Rutgers | Therapeutic polyesters and polyamides. |
AU2001279064A1 (en) * | 2000-07-27 | 2002-02-13 | Rutgers, The State University | Therapeutic azo-compounds for drug delivery |
-
2001
- 2001-07-27 AU AU2001279064A patent/AU2001279064A1/en not_active Abandoned
- 2001-07-27 US US09/917,595 patent/US6602915B2/en not_active Expired - Fee Related
- 2001-07-27 WO PCT/US2001/023748 patent/WO2002009769A2/en active Application Filing
-
2003
- 2003-08-25 US US10/647,701 patent/US20040044125A1/en not_active Abandoned
- 2003-11-10 US US10/712,416 patent/US20040228832A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6602915B2 (en) | 2003-08-05 |
WO2002009769A2 (en) | 2002-02-07 |
US20020071821A1 (en) | 2002-06-13 |
US20040228832A1 (en) | 2004-11-18 |
US20040044125A1 (en) | 2004-03-04 |
WO2002009769A3 (en) | 2002-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001279064A1 (en) | Therapeutic azo-compounds for drug delivery | |
AU2001235009A1 (en) | Drug delivery apparatus | |
AU2001258095A1 (en) | Drug delivery systems for photodynamic therapy | |
AU2001264887A1 (en) | Drug delivery device | |
AU2001238386A1 (en) | Medication delivery devices | |
EP1545662B8 (en) | Drug delivery system | |
AU2001261425A1 (en) | Cases for medication delivery devices | |
AU2123200A (en) | Drug delivery device | |
AU4985600A (en) | Drug delivery device | |
AU2002246925A1 (en) | Therapeutic delivery balloon | |
AU2001273376A1 (en) | Drug delivery device for animals | |
AU2002352344A1 (en) | Medicament delivery assembly | |
AU4947100A (en) | Drug delivery device | |
AU2002343555A1 (en) | Eutectic-based self-nanoemulsified drug delivery system | |
HK1077523A1 (en) | Proliposomal drug delivery system | |
AUPR573001A0 (en) | Lymphatic drug delivery system | |
AU2001277171A1 (en) | Catheter for target specific drug delivery | |
AU2001270963A1 (en) | Transdermal drug delivery system | |
AU2001243515A1 (en) | Combination drug therapy | |
AU2002243290A1 (en) | Transluminal drug delivery catheter | |
AU6503399A (en) | Drug delivery catheter | |
AU2002222138A1 (en) | Drug delivery system | |
AU2003285550A1 (en) | Drug delivery system | |
AU2001244854A1 (en) | Local drug delivery | |
AU2002210580A1 (en) | Drug delivery system |